Next Article in Journal
Periodontal Bone-Ligament-Cementum Regeneration via Scaffolds and Stem Cells
Next Article in Special Issue
Fibroblast Growth Factor Receptor Signaling in Skin Cancers
Previous Article in Journal
Molecular Profiling of Inflammatory Bowel Disease: Is It Ready for Use in Clinical Decision-Making?
Previous Article in Special Issue
Cancer Mutations in FGFR2 Prevent a Negative Feedback Loop Mediated by the ERK1/2 Pathway
Open AccessReview

FGF19–FGFR4 Signaling in Hepatocellular Carcinoma

1
Department of Biosciences, Comsats University, Islamabad 45550, Pakistan
2
Division of Medical Oncology, Department of Internal Medicine, Gachon University Gil Medical Center, Incheon 21565, Korea
3
Department of Genome Medicine and Science, College of Medicine, Gachon University, Incheon 21565, Korea
*
Authors to whom correspondence should be addressed.
Cells 2019, 8(6), 536; https://doi.org/10.3390/cells8060536
Received: 10 May 2019 / Revised: 28 May 2019 / Accepted: 29 May 2019 / Published: 4 June 2019
(This article belongs to the Special Issue Fibroblast Growth Factor Receptor (FGFR) Signaling Pathway in Tumor)
Hepatocellular carcinoma (HCC) is the sixth most common type of cancer, with an increasing mortality rate. Aberrant expression of fibroblast growth factor 19–fibroblast growth factor receptor 4 (FGF19–FGFR4) is reported to be an oncogenic-driver pathway for HCC patients. Thus, the FGF19–FGFR4 signaling pathway is a promising target for the treatment of HCC. Several pan-FGFR (1–4) and FGFR4-specific inhibitors are in different phases of clinical trials. In this review, we summarize the information, recent developments, binding modes, selectivity, and clinical trial phases of different available FGFR4/pan-FGF inhibitors. We also discuss future perspectives and highlight the points that should be addressed to improve the efficacy of these inhibitors. View Full-Text
Keywords: prognosis; FGF19; FGFR4; HCC; inhibitors prognosis; FGF19; FGFR4; HCC; inhibitors
Show Figures

Figure 1

MDPI and ACS Style

Raja, A.; Park, I.; Haq, F.; Ahn, S.-M. FGF19–FGFR4 Signaling in Hepatocellular Carcinoma. Cells 2019, 8, 536.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop